Document is current
Any future updates will be listed below
-
Authors
Kishi, Taro https://orcid.org/0000-0002-9237-2236
Koebis, Michinori
Sugawara, Michiko
Kawatsu, Yuka
Taninaga, Takehiro
Iwata, Nakao https://orcid.org/0000-0003-3189-6076
- License Information
-
More Information
Article History
Received: 19 September 2023
Revised: 2 September 2024
Accepted: 2 September 2024
First Online: 14 September 2024
Competing interests
: TK has received speaker’s honoraria from Eisai Co., Ltd, Janssen Pharmaceutical K.K., Meiji Seika Pharma Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Sumitomo Pharma Co., Ltd, Takeda Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Corporation, KYOWA Pharmaceutical Industry Co., Ltd, Yoshitomiyakuhin Corporation, and Viatris, and research grants from Eisai Co., Ltd, Grants-in-Aid for Scientific Research (C) (19K08082 and 23K06998), Japan Agency for Medical Research and Development (JP22dk0307107, JP22wm0525024, JP23dk0307122 and 24dk0307129), and the Japanese Ministry of Health, Labour and Welfare (21GC1018). MK, MS, YK, and TT are employees of Eisai Co., Ltd. NI has received speaker’s honoraria from Eisai Co., Ltd, Janssen Pharmaceutical K.K., Meiji Seika Pharma Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Sumitomo Pharma Co., Ltd, Takeda Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Corporation, and Viatris Inc., and research grants from Daiichi Sankyo Co., Ltd, Eisai Co., Ltd, Meiji Seika Pharma Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Sumitomo Pharma Co., Ltd, Takeda Pharmaceutical Co., Ltd, and Mitsubishi Tanabe Pharma Corporation.
